Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisporivir plus peginterferon alfa-2a and ribavirin in treatment-naïve chronic hepatitis C genotype 1
2010-022867-37Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hepatitis C virus infection comparing Alisporivir + peginterferon alfa-2a + ribavirin with Placebo + peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: Sustained virologic response at Week 12 (SVR12). Started Mar 2011; status: completed.
02
Drugs
alisporivir
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on 2010-022867-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022867-37.